Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Outstanding (2016 - 2025)

Ultragenyx Pharmaceutical has reported Shares Outstanding over the past 11 years, most recently at $96.6 million for Q4 2025.

  • Quarterly Shares Outstanding rose 4.43% to $96.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.6 million through Dec 2025, up 4.43% year-over-year, with the annual reading at $96.6 million for FY2025, 4.43% up from the prior year.
  • Shares Outstanding was $96.6 million for Q4 2025 at Ultragenyx Pharmaceutical, roughly flat from $96.4 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $96.6 million in Q4 2025 and troughed at $67.4 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $71.8 million (2023), against an average of $79.6 million.
  • Year-over-year, Shares Outstanding grew 1.23% in 2022 and then rose 28.92% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $69.3 million in 2021, then rose by 1.23% to $70.2 million in 2022, then increased by 17.24% to $82.3 million in 2023, then rose by 12.39% to $92.5 million in 2024, then rose by 4.43% to $96.6 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Shares Outstanding are $96.6 million (Q4 2025), $96.4 million (Q3 2025), and $96.4 million (Q2 2025).